New Novartis data show Cosentyx demonstrated sustained superiority in skin clearance (PASI 90) versus Stelara at Week 52 - Late-breaking data at AAD show Cosentyx® remains superior to Stelara® in achieving almost clear skin (PASI 90) at Week 16 and at one year in 76.2% versus 60.6% of moderate to severe psoriasis patients(1)- Exploratory analysis showed a higher percentage of Cosentyx patients achieved completely clear skin (PASI 100) compared to Stelara patients at Week 52(1)- Cosentyx is the first and only human IL-17A antagonist approved by the FDA for adult patients with moderate to severe plaque psoriasis, active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA)

EAST HANOVER, N.J., March 5, 2016 /PRNewswire/ -- Novartis today announced new late-breaking data from the head-to-head CLEAR study, showing that Cosentyx® (secukinumab) was superior in achieving a key secondary efficacy endpoint of near clear skin on the Psoriasis Area Severity Index (PASI 90) in significantly more moderate to severe psoriasis patients compared to Stelara®* (ustekinumab) at Week 52.1 These findings were presented for the first time at the American Academy of Dermatology (AAD) 74th Annual Meeting in Washington, D.C. Cosentyx is the first and only fully human interleukin-17A (IL-17A) antagonist approved to treat adult patients with moderate to severe plaque...